End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
64,800 KRW | -4.85% | -6.09% | -6.22% |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's share price in relation to its net book value makes it look relatively cheap.
- For the past twelve months, EPS forecast has been revised upwards.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.22% | 432M | - | ||
+5.48% | 69.91B | A | ||
+12.55% | 9.24B | A- | ||
-13.75% | 5.05B | A- | ||
+42.38% | 4.47B | - | ||
+4.51% | 3.92B | B- | ||
-19.05% | 2.41B | C- | ||
-28.72% | 2.23B | - | ||
+11.13% | 2.02B | - | - | |
+6.53% | 1.66B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- A170900 Stock
- Ratings Dong-A ST Co., Ltd.